EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Luis Miguel Juárez-Salcedo iD, Santosh Nimkar iD, Ana María Corazón, Samir Dalia

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25147580 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Luis Miguel Juárez-Salcedo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, La Princesa University Hospital, 28006 Madrid, Spain. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Currently, a significant percentage of patients with DLBCL are refractory or relapse after a first line of immunochemotherapy. Second relapses after autologous stem cell transplantation or chimeric antigen receptor T-cell therapies present few treatment options and do not yield good results. New molecules have entered the immunotherapy arsenal. Loncastuximab tesirine comprises a humanized anti-CD19 monoclonal conjugated antibody, which consists of an anti-CD19 antibody and cytotoxic alkylating agent, SG3199. Several studies have proven its efficacy in the treatment of refractory cases of DLBCL with a good safety profile, with the main adverse effects being neutropenia, thrombopenia, and liver enzyme involvement. In this review, we explain the mechanism of action of this molecule, the clinical data that have led to its acceptance by the FDA, and the new therapeutic options that are proposed in association with this drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntibodies, Monoclonal, HumanizedHumansNeoplasm Recurrence, LocalAntigens, CD19ImmunoconjugatesBenzodiazepines

Stichwörter der Autor:innen

antibody–drug conjugatediffuse large-B-cell lymphomaimmunotherapyloncastuximab tesirinerefractory/relapse

Substanzen

Antibodies, Monoclonal, Humanizedloncastuximab tesirineAntigens, CD19ImmunoconjugatesBenzodiazepines

Autor:innen und Institutionen

  • Hematology Department, La Princesa University Hospital, 28006 Madrid, Spain.
  • College of Osteopathic Medicine, Kansas City University, Kansas City, MO 64804, USA.
  • Primary Care Medicine, Adelfas Primary Care Center, 28007 Madrid, Spain.
  • Hematology/Oncology Department, Mercy Clinic Oncology and Hematology, Joplin, MI 73120, USA.

ORCID-Profile: Luis Miguel Juárez-Salcedo, Santosh Nimkar

Zitieren

APA

Juárez-Salcedo, L. M., Nimkar, S., Corazón, A. M., & Dalia, S. (2024). Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147580

Vancouver

Juárez-Salcedo LM, Nimkar S, Corazón AM, Dalia S. Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147580

BibTeX
@article{JurezSalcedo2024,
  author = {Juárez-Salcedo, Luis Miguel and Nimkar, Santosh and Corazón, Ana María and Dalia, Samir},
  title = {Loncastuximab Tesirine in the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25147580}
}
Kostenlos starten →